Rapid communication · 29 May 2025
Conference abstractPublished 2012
Phagocyte-like NADPH oxidase mediates islet dysfunction in models of impaired insulin secretion and diabetes: So, is it �druggable�?
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Excessive generation of reactive oxygen species [ROS] is considered central to the development of cellular dysfunction in diabetes. The generation of free radicals is relatively low under physiologic conditions; however, increased levels of circulating glucose, lipids or proinflammatory cytokines promote intracellular accumulation of superoxides, leading to cellular dysregulation. Although mitochondria remain the primary source for free radicals, recent evidence implicates phagocyte-like NADPH oxidase [Nox] as a principal source of extra-mitochondrial ROS. Nox is a highly regulated membrane-associated protein complex that promotes a one-electron reduction of oxygen to superoxide anion involving oxidation of cytosolic NADPH. The Nox holoenzyme consists of membrane and cytosolic components. The membrane-associated catalytic core consists of gp91phox/p22phox, and the cytosolic regulatory core includes p47phox/ p67phox/p40phox/Rac1. Following stimulation, the cytosolic core translocates to the membrane for association with the catalytic core for activation of Nox. To this end, our recent findings suggested that exposure of isolated beta-cells to glucolipotoxic conditions or proinflammatory cytokines results in the activation of cytosolic core of Nox [p47phox phosphorylation and Rac1 activation] culminating in the generation of Nox-derived ROS. Importantly, our data are suggestive of an accelerated Nox signaling cascade in islets derived from animal models of obesity and diabetes [ZDF Rat] and type 2 DM human donors. It is noteworthy that in vitro approaches involving the use of Rac1 inhibitors [NSC23766] appear to halt the progression of mitochondrial defects and loss in beta-cell viability induced by glucolipotoxic conditions and cytokines. Even though these advancements paint a positive picture that inhibitors of Rac1-Nox-ROS signaling pathway could serve as novel therapeutic tools to attenuate islet dysfunction under the duress of glucolipotoxic or cytokine exposure conditions; they could be met with some skepticism given the indispensable nature of Rac1 signaling axis in beta-normal cell function and survival. Potential therapeutic modalities that are being considered to target Nox and prevent intracellular oxidative stress and beta-cell demise will be discussed.
Subjects
Diabetes & EndocrinologyAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
More from this journal
The newest in Journal of Diabetes & Metabolism.
Rapid communication · 29 May 2025
Genetic and epigenetic markers for gdm risk
Short communication · 29 May 2025
Metabolic syndrome: Diet, timed eating, supplements
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalJournal of Diabetes & Metabolism
- SubjectDiabetes & Endocrinology
- BylineArticles whose byline prints “Anjan Kowluru”